Therapy News and Research

RSS

Feinstein Institute to train clinicians on how to better care for patients with schizophrenia

The Zucker Hillside Hospital campus of the Feinstein Institute for Medical Research has been approved for a $9.3+ million federal grant to train clinicians on how to better care for patients with schizophrenia.

26 Jun 2012

Combination regimens trump monotherapy in fight against HIV transmission

A two- or three-drug combination is more effective at reducing intrapartum HIV acquisition than zidovudine monotherapy in babies who are at high risk for transmission, a study in The New England Journal of Medicine shows.

25 Jun 2012

HIV therapy affects bone mass within 2 years

Young men receiving antiretroviral therapy for recently diagnosed HIV are more likely to have low bone mineral density than are other men of a similar age, US researchers report.

25 Jun 2012

Enrollment commences in Stealth Peptides' Bendavia Phase II clinical study for acute STEMI

Stealth Peptides Incorporated, a privately held biopharmaceutical company developing innovative therapies for cardiovascular disease and its complications, announced today that the first patient was enrolled in its multinational Phase II clinical study with Bendavia focused on ischemia reperfusion and microvascular injuries for patients experiencing acute ST-segment elevation myocardial infarction.

25 Jun 2012

Afirma gene expression test can reduce unnecessary thyroid cancer surgeries

Veracyte, Inc., a molecular diagnostics company that is pioneering the emerging field of molecular cytology, today announced results from a large, prospective, multicenter study, which demonstrated the potential for the Afirma® Gene Expression Classifier, a gene expression test, to reduce the large number of unnecessary surgeries in thyroid cancer diagnosis by more than half.

25 Jun 2012

Deep brain stimulation reduces binge eating

Deep brain stimulation reduces binge eating in mice, suggesting that this surgery, which is approved for treatment of certain neurologic and psychiatric disorders, may also be an effective therapy for obesity. Presentation of the results will take place Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

25 Jun 2012

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal motor neuropathy (MMN). This is the first immunoglobulin treatment approved for MMN patients in the United States, and it was approved for use with MMN patients in Europe in 2011.

From Baxter International Inc. 25 Jun 2012

MAP Pharmaceuticals completes End-of-Review meeting with FDA for LEVADEX NDA

MAP Pharmaceuticals, Inc. today announced that the Company completed an End-of-Review meeting with the United States Food and Drug Administration (FDA) for its New Drug Application (NDA) for LEVADEX (dihydroergotamine) inhalation aerosol.

25 Jun 2012

Pfizer, Bristol-Myers Squibb receive FDA CRL for ELIQUIS NDA

Bristol-Myers Squibb Company and Pfizer announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

25 Jun 2012

Positive results from Lexicon’s LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc., announced today that LX4211, an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), showed substantial, dose-dependent, statistically-significant reductions in hemoglobin A1c (HbA1c) in a Phase 2b trial in patients diagnosed with poorly-controlled type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy.

25 Jun 2012

Study reveals previously unknown function of Thbd-aPC pathway in radiation mitigation

New research in Nature Medicine shows that boosting a protein pathway in the body's blood making system protects mice from otherwise fatal radiation poisoning.

25 Jun 2012

De novo somatic gene mutations likely to cause hemimegalencephaly

Hemimegalencephaly is a rare but dramatic condition in which the brain grows asymmetrically, with one hemisphere becoming massively enlarged. Though frequently diagnosed in children with severe epilepsy, the cause of hemimegalencephaly is unknown and current treatment is radical: surgical removal of some or all of the diseased half of the brain.

25 Jun 2012

Overactive thyroid gland may increase risk of hospitalization for heart and blood-vessel disease

An overactive thyroid gland, or hyperthyroidism, may increase the risk of hospitalization for heart and blood-vessel disease even after surgery to remove the gland, according to a new study. The results will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.

25 Jun 2012

GI Dynamics announces clinical data about EndoBarrier Therapy at ASMBS meeting

GI Dynamics, Inc. announced today that clinical data about EndoBarrier Therapy, a breakthrough treatment for type 2 diabetes and/or obesity, was presented at the 29th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS) in San Diego.

23 Jun 2012

Deferasirox reduces elevated iron levels in patients with myelodysplastic syndrome

Researchers at Moffitt Cancer Center and colleagues at six other institutions have recently tested a treatment for patients with myelodysplastic syndrome, or MDS, a blood-related malignancy that involves the ineffective production of blood cells, leaving patients anemic and in need of frequent blood transfusions. Because the body has no natural means to reduce iron that accumulates from repeated transfusions, patients' organs can become iron overloaded, leading to heart failure, liver injury, susceptibility to infection, and other complications.

23 Jun 2012

GMCSF linked with rapid cognitive recovery in patients with cancer

Growth factors shown to cure Alzheimer's disease in a mouse model and administered to cancer patients as part of their treatment regimen were linked to significant improvements in the patients' cognitive function following stem cell transplantation, a preliminary clinical study reports.

23 Jun 2012

Scientists recommend new type of therapeutic approach to dementia

Scientists at Charité - Universitätsmedizin Berlin have succeeded in recommending a new type of therapeutic approach to dementia. The study published in the journal Neurology shows that immune reactions against the body's own nerve cells can be the cause of advanced dementia and an appropriate immune suppressive therapy can develop with significant effectiveness.

23 Jun 2012

WCMC researchers devise innovative boxer-like strategy to fight multiple myeloma

Weill Cornell Medical College researchers have devised an innovative boxer-like strategy, based on the serial use of two anti-cancer drugs, to deliver a one-two punch to first weaken the defenses of multiple myeloma and then deliver the final knock-out punch to win the fight.

23 Jun 2012

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Genentech, a member of the Roche Group, announced today that people with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.

23 Jun 2012

Disorganized cancers more difficult to treat and consistently result in lower survival rates

Medical researchers at the University of Alberta reviewed test results from thousands of patients with various types of cancer and discovered that "disorganized" cancers were more difficult to treat and consistently resulted in lower survival rates.

23 Jun 2012

Therapy News and Research

Feinstein Institute to train clinicians on how to better care for patients with schizophrenia

Combination regimens trump monotherapy in fight against HIV transmission

HIV therapy affects bone mass within 2 years

Enrollment commences in Stealth Peptides' Bendavia Phase II clinical study for acute STEMI

Afirma gene expression test can reduce unnecessary thyroid cancer surgeries

Deep brain stimulation reduces binge eating

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

MAP Pharmaceuticals completes End-of-Review meeting with FDA for LEVADEX NDA

Pfizer, Bristol-Myers Squibb receive FDA CRL for ELIQUIS NDA

Positive results from Lexicon’s LX4211 Phase 2b trial on type 2 diabetes

Study reveals previously unknown function of Thbd-aPC pathway in radiation mitigation

De novo somatic gene mutations likely to cause hemimegalencephaly

Overactive thyroid gland may increase risk of hospitalization for heart and blood-vessel disease

GI Dynamics announces clinical data about EndoBarrier Therapy at ASMBS meeting

Deferasirox reduces elevated iron levels in patients with myelodysplastic syndrome

GMCSF linked with rapid cognitive recovery in patients with cancer

Scientists recommend new type of therapeutic approach to dementia

WCMC researchers devise innovative boxer-like strategy to fight multiple myeloma

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Disorganized cancers more difficult to treat and consistently result in lower survival rates

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News